Literature DB >> 32920056

Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma: A retrospective analysis.

Richard P Ramonell1, F Eun-Hyung Lee1, Joshua M Levy2, Merin Kuruvilla3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32920056      PMCID： PMC9127982          DOI： 10.1016/j.anai.2020.09.005

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.248


× No keyword cloud information.
  10 in total

1.  The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia.

Authors:  Hector Ortega; Geoffrey Chupp; Philip Bardin; Arnaud Bourdin; Gilles Garcia; Benjamin Hartley; Steve Yancey; Marc Humbert
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

2.  Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma.

Authors:  Florence N Schleich; Laurence Seidel; Jocelyne Sele; Maite Manise; Valerie Quaedvlieg; Alain Michils; Renaud Louis
Journal:  Thorax       Date:  2010-07-29       Impact factor: 9.139

3.  Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.

Authors:  Adel H Mansur; Sapna Srivastava; Verity Mitchell; Julie Sullivan; Ismail Kasujee
Journal:  Respir Med       Date:  2017-01-25       Impact factor: 3.415

4.  Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Authors:  Mario Castro; Jonathan Corren; Ian D Pavord; Jorge Maspero; Sally Wenzel; Klaus F Rabe; William W Busse; Linda Ford; Lawrence Sher; J Mark FitzGerald; Constance Katelaris; Yuji Tohda; Bingzhi Zhang; Heribert Staudinger; Gianluca Pirozzi; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Asif Khan; Jingdong Chao; Renata Martincova; Neil M H Graham; Jennifer D Hamilton; Brian N Swanson; Neil Stahl; George D Yancopoulos; Ariel Teper
Journal:  N Engl J Med       Date:  2018-05-21       Impact factor: 91.245

5.  External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma.

Authors:  A H Wagener; S B de Nijs; R Lutter; A R Sousa; E J M Weersink; E H Bel; P J Sterk
Journal:  Thorax       Date:  2014-11-24       Impact factor: 9.139

6.  Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Authors:  Nicola A Hanania; Oral Alpan; Daniel L Hamilos; John J Condemi; Irmarie Reyes-Rivera; Jin Zhu; Karin E Rosen; Mark D Eisner; Dennis A Wong; William Busse
Journal:  Ann Intern Med       Date:  2011-05-03       Impact factor: 25.391

7.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

Authors:  Nicola A Hanania; Sally Wenzel; Karin Rosén; Hsin-Ju Hsieh; Sofia Mosesova; David F Choy; Preeti Lal; Joseph R Arron; Jeffrey M Harris; William Busse
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

8.  Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy.

Authors:  Yu-Chen Huang; Chih-Ming Weng; Meng-Jung Lee; Shu-Min Lin; Chun-Hua Wang; Han-Pin Kuo
Journal:  Clin Exp Allergy       Date:  2018-09-11       Impact factor: 5.018

Review 9.  The Efficacy and Safety of Antiinterleukin 13, a Monoclonal Antibody, in Adult Patients With Asthma: A Systematic Review and Meta-Analysis.

Authors:  Jian Luo; Dan Liu; Chun-Tao Liu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

Review 10.  Dupilumab in the management of moderate-to-severe asthma: the data so far.

Authors:  Pilar Barranco; Elsa Phillips-Angles; Javier Dominguez-Ortega; Santiago Quirce
Journal:  Ther Clin Risk Manag       Date:  2017-09-01       Impact factor: 2.423
  10 in total
  2 in total

1.  Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series.

Authors:  Geneviève Pelletier; Krystelle Godbout; Marie-Ève Boulay; Louis-Philippe Boulet; Mathieu C Morissette; Andréanne Côté
Journal:  J Asthma Allergy       Date:  2022-05-19

Review 2.  Utilizing Predictive Inflammatory Markers for Guiding the Use of Biologicals in Severe Asthma.

Authors:  Martin Runnstrom; Hilary Pitner; Jennifer Xu; F Eun-Hyung Lee; Merin Kuruvilla
Journal:  J Inflamm Res       Date:  2022-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.